Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Increased to $17.00 by Analysts at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […]

Related Keywords

Christopher Gibson ,Tina Marriott ,Investment Management ,Needham Company ,Recursion Pharmaceuticals Inc ,Vanguard Group Inc ,Insider Transactions At Recursion Pharmaceuticals ,News Ratings For Recursion Pharmaceuticals Daily ,Recursion Pharmaceuticals Company Profile ,Sumitomo Mitsui Trust Holdings Inc ,Jpmorgan Chase Co ,Blackrock Inc ,Recursion Pharmaceuticals ,Recursion Pharmaceuticals Price Performance ,Hedge Funds Weigh In On Recursion Pharmaceuticals ,Free Report ,Sumitomo Mitsui Trust Holdings ,Mitsui Trust Holdings ,Get Free Report ,Recursion Pharmaceuticals Daily ,Nasdaq Rxrx ,Rxrx ,Medical ,Boost Price Target ,Needham Company Llc ,